Breaking News from RAVE: Roflumilast Cream Shows Continued Improvements in AD Through 56 Weeks
With the July 2024 Prescription Drug User Fee Act (PDUFA) target action date for roflumilast cream, 0.15% in atopic dermatitis (AD) drawing near, Melissa Gooderham, MSc, MD, FRCPC, Medical Director at the SKiN Centre for Dermatology in Peterborough, Ontario, Canada, shares new data from the INTEGUMENT-OLE long-term, open-label study of roflumilast cream, 0.15% for the […]